SCHEMBL769915

SCHEMBL769915

CC(C)c1ccc(CNc2ccc3c(c2)ncn3-c2ccc(OC(C)(C)C)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.61
NPC1 O15118 11/20 0.61
POLB P06746 1/20 0.61
MAPT P10636 11/20 0.52
KDM4E B2RXH2 9/20 0.52
ALDH1A1 P00352 7/20 0.52
HPGD P15428 6/20 0.52
TDP1 Q9NUW8 4/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
HTT P42858 2/20 0.52
MAPK1 P28482 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
GAA P10253 3/20 0.52
KIT P10721 2/20 0.52
FLT3 P36888 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.51
LMNA P02545 2/20 0.50
ALOX15 P16050 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL769761 0.89 NPC1 (0.64) RAB9ANPC1POLBMAPTKDM4E
SCHEMBL770154 0.89 RAB9A (0.64) RAB9ANPC1POLBMAPTKDM4E
SCHEMBL769548 0.89 MAPT (0.64) RAB9ANPC1POLBMAPTKDM4E
SCHEMBL770450 0.88 MAPT (0.65) RAB9ANPC1POLBMAPTKDM4E
SCHEMBL769479 0.87 RAB9A (0.64) RAB9ANPC1POLBMAPTKDM4E
SCHEMBL769960 0.86 RAB9A (0.61) RAB9ANPC1POLBMAPTKDM4E
SCHEMBL769963 0.86 RAB9A (0.61) RAB9ANPC1POLBMAPTKDM4E
SCHEMBL769840 0.86 RAB9A (0.61) RAB9ANPC1POLBMAPTKDM4E
SCHEMBL769029 0.86 RAB9A (0.68) RAB9ANPC1POLBMAPTKDM4E
SCHEMBL770573 0.84 RAB9A (0.58) RAB9ANPC1POLBMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US claimed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US claimed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection ZC3HAV1, GZMB, GTF3C3 RAB9A 3973/4885NPC1 337/4885POLB 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.